In the search for new anticancer drugs. VII. Platinum complexes of diaziridines and azetidine.
Three new diaziridine platinum(II) complexes (4a)-(4c), and a new azetidine platinum(II) complex (3b) were synthesized and tested against the lymphocytic leukemia P388 in mice. (formula; see text) Moderate to good activity was found for all compounds as evidenced by a T/C value of 162 at a dose of 32 mg/kg for (3b), 190 at a dose of 32 mg/kg for (4a), 139 at a dose of 4 mg/kg for (4b), and 142 at a dose of 20 mg/kg for (4c).
D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis* / Q000627:therapeutic use; D001384:Azetidines / Q000138:chemical synthesis* / Q000627:therapeutic use; D001385:Azetines / Q000138:chemical synthesis*; D001388:Aziridines / Q000138:chemical synthesis* / Q000627:therapeutic use; D001389:Azirines / Q000138:chemical synthesis*; D007941:Leukemia P388 / Q000188:drug therapy; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D009944:Organoplatinum Compounds / Q000138:chemical synthesis* / Q000627:therapeutic use; D013329:Structure-Activity Relationship
D000970:Antineoplastic Agents; D001384:Azetidines; D001385:Azetines; D001388:Aziridines; D001389:Azirines; D009944:Organoplatinum Compounds; C042302:dimethylaziridine platinum(II); C042303:diethyldiaziridine platinum(II); C042304:azetidine platinum(II)